Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
ACS Nano. 2023 May 23;17(10):9090-9109. doi: 10.1021/acsnano.2c12230. Epub 2023 May 12.
Atherosclerosis (AS) is a systemic disease characterized by lipid deposition in the blood vessel wall that urgently requires effective and safe therapeutic drugs for long-term treatment. An essential oil monomer-1,8-cineole (CIN) with ameliorative effects on vascular injuries has considerable potential for preventing the progression of AS because of its antioxidant, anti-inflammation, and cholesterol regulatory effects. However, the high volatility and instability of CIN result in low oral bioavailability and a short half-life, thereby limiting its clinical application. We formulated a nanoemulsion using a polysaccharide-protein/protein complex (dextran-bovine serum albumin/protamine, DEX-BSA/PTM) as an emulsifier, with vitamin B12 (VB) as the ligand to facilitate the transportation across the small intestine. An emulsion preparation method using a microjet followed by ultraviolet irradiation was developed to obtain the CIN-loaded oral nanoemulsion CIN@DEX-BSA/PTM/VB. The nanoemulsion improved the stability of CIN both and , prolonged the retention time in the gastrointestinal tract (GIT), and enhanced the permeability across the mucus layer and intestinal epithelial cells to increase oral bioavailability and plaque accumulation of CIN. Validated in an AS mouse model, CIN@DEX-BSA/PTM/VB achieved prominent therapeutic efficacy combating AS. This study highlights the advantages of DEX-BSA/PTM and VB in the development of nanoemulsions for CIN and provides a promising oral nanoplatform for the delivery of essential oils.
动脉粥样硬化(AS)是一种全身性疾病,其特征是血管壁内脂质沉积,迫切需要有效和安全的治疗药物进行长期治疗。具有改善血管损伤作用的精油单体-1,8-桉叶油醇(CIN)由于其抗氧化、抗炎和调节胆固醇作用,具有预防 AS 进展的巨大潜力。然而,CIN 的高挥发性和不稳定性导致其口服生物利用度低,半衰期短,从而限制了其临床应用。我们使用多糖-蛋白质/蛋白质复合物(葡聚糖-牛血清白蛋白/鱼精蛋白,DEX-BSA/PTM)作为乳化剂,用维生素 B12(VB)作为配体,制定了一种纳米乳液配方,以促进穿过小肠。采用微射流后紫外照射的乳液制备方法,得到负载 CIN 的口服纳米乳液 CIN@DEX-BSA/PTM/VB。纳米乳液提高了 CIN 的稳定性,延长了在胃肠道(GIT)中的保留时间,并增强了穿过黏液层和肠上皮细胞的通透性,从而提高了 CIN 的口服生物利用度和斑块蓄积。在 AS 小鼠模型中验证,CIN@DEX-BSA/PTM/VB 实现了对抗 AS 的显著治疗效果。本研究突出了 DEX-BSA/PTM 和 VB 在 CIN 纳米乳液开发中的优势,为精油的输送提供了一种有前途的口服纳米平台。